AestheticsFeatured Articles

What are the Skincare Benefits of Niacinamide?

By September 28, 2020No Comments

Featured Article

Featured Article

A 2016 study from Journal of Drugs in Dermatology suggests that a topical cream containing retinol 0.5% in combination with niacinamide, resveratrol, and hexylresorcinol is efficacious and tolerable for skin brightening/anti-aging when used with a complementary skin care regimen including SPF 30 sun protection.

Read more

A 2016 study from Journal of Drugs in Dermatology (“Efficacy and Tolerability of a Skin Brightening/Anti-Aging Cosmeceutical Containing Retinol 0.5%, Niacinamide, Hexylresorcinol, and Resveratrol“), which was recently cited in an article on Prevention.com, suggests that a topical cream containing retinol 0.5% in combination with niacinamide, resveratrol, and hexylresorcinol is efficacious and tolerable for skin brightening/anti-aging when used with a complementary skin care regimen including SPF 30 sun protection. 

Patricia Farris MD, Joshua Zeichner MD, and Diane Berson MD

 

Consumers are increasingly interested in over-the-counter skin care products that can improve the appearance of photodamaged and aging skin. This 10-week, open-label, single- center study enrolled 25 subjects with mild to moderate hyperpigmentation and other clinical stigmata of cutaneous aging including fine lines, sallowness, lack of clarity, and wrinkling. Their mean age was 53.4±7.7 years. The test product contained retinol 0.5% in combination with niacinamide 4.4%, resveratrol 1%, and hexylresorcinol 1.1% in a moisturizing base. Subjects were provided a skin care regimen including a cleanser, hydrating serum, moisturizer, and an SPF 30 sunscreen for daily use. The test product was applied only at night.

The use of this skin brightening/anti-aging cosmeceutical was found to provide statistically significant improvements in all efficacy endpoints by study end. Fine lines, radiance, and smoothness were significantly improved as early as week 2 (P<.001). By week 4, hyperpigmentation, overall skin clarity, evenness of skin tone, and wrinkles showed statistically significant improvement compared to baseline. Mild retinoid dermatitis including flaking and redness occurred early in the study as reflected by tolerability scores. By week 10, subjects reported no stinging, itching, dryness, or tingling.

The results of this open-label clinical study suggest that a topical cream containing retinol 0.5% in combination with niacinamide, resveratrol, and hexylresorcinol is efficacious and tolerable for skin brightening/anti-aging when used with a complementary skin care regimen including SPF 30 sun protection.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD About The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas. The images is of sarcoidosis among different skin tones

Decoding Derm: What’s the Diagnosis?

| Featured Articles, Inclusive Dermatology Atlas, Latest News | No Comments
Test Your Knowledge! Join Dr. Alexis Carrington, Chief Dermatology Resident at George Washington University, to help understand dermatologic conditions across all skin tones. Decoding Derm: What’s the Diagnosis is a…

JDD Re:View With Dr. Beer

| Featured Articles, JDD Re:View, Latest News | No Comments
Title: Novel Treatments and Clinical Insights Shaping Dermatology As we head into the new year, it’s important to highlight some of the pieces that helped clarify the role of novel…
Journal of Drugs in Dermatology author Dr. Andrew Blauvelt speaking about cutting‑edge psoriasis science during George Washington University’s Dermatology Translational Science Lecture Series. The title of the presentation is Curing Psoriasis.

JDD Author and Psoriasis Expert Andrew Blauvelt, MD, MBA: Watch His “Curing Psoriasis” Translational Lecture Series

| Featured Articles, Latest News | No Comments
See JDD author Dr. Andrew Blauvelt bring cutting‑edge psoriasis science to life in GWU’s Dermatology Translational Science Lecture Series, and learn about his new Nature study on high‑induction risankizumab dosing.…

Leave a Reply